Polyclonal Antibody to Caspase 3 (CASP3)
| Code | Size | Price |
|---|
| PAA626Mu01-20ul | 20ul | £82.00 |
Quantity:
| PAA626Mu01-100ul | 100ul | £152.00 |
Quantity:
| PAA626Mu01-200ul | 200ul | £204.00 |
Quantity:
| PAA626Mu01-1ml | 1ml | £464.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CPP32; CPP32B; SCA1; Apoptain; Yama; Apoptosis-Related Cysteine Peptidase; Cysteinyl Aspartate Specific Proteinases 3; SREBP cleavage activity 1
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Caspase 3
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
- https://link.springer.com/article/10.1007/s00210-018-01597-9" - Side effects of frequently used oral antidiabetics on wound healing in vitro
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Caspase 3 (CASP3) | RPA626Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||